Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
The objective of this study is to identify the following in adult epilepsy participants with
 partial-onset seizures (with or without secondary generalized seizures) or primary
 generalized Tonic-clonic seizures who receive long-term treatment with Fycompa:

 1. unknown adverse drug reactions (ADRs);

 2. occurrence of ADRs;

 3. factors that are likely to affect safety and efficacy;

 4. occurrence of dizziness, balance disorders, ataxia, muscle relaxation-related adverse
 events, and falls as priority investigation items;

 5. occurrence of psychiatric adverse events as priority investigation items (eg,
 aggression).
Inclusion Criteria:

 -  Epilepsy participants at least 18 years of age with:

 -  Partial seizures (with or without secondary generalized seizures)

 -  Primary generalized Tonic-clonic seizures

 Exclusion Criteria:

 -  Participants previously treated with Fycompa